Shares of KemPharm Inc. (NASDAQ:KMPH) have earned an average broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
Brokers have set a twelve-month consensus price objective of $26.67 for the company and are forecasting that the company will post ($0.70) earnings per share for the current quarter, according to Zacks. Zacks has also given KemPharm an industry rank of 87 out of 265 based on the ratings given to related companies.
Several equities analysts have commented on the stock. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $11.00 price target on shares of KemPharm in a research note on Tuesday, June 14th. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Tuesday, August 16th. Finally, Canaccord Genuity restated a “buy” rating on shares of KemPharm in a research report on Wednesday, August 10th.
In other KemPharm news, EVP Daniel L. Cohen bought 10,000 shares of the stock in a transaction dated Tuesday, September 6th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the executive vice president now owns 1,310 shares in the company, valued at approximately $6,222.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.80% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Spark Investment Management LLC raised its position in KemPharm by 195.1% in the second quarter. Spark Investment Management LLC now owns 141,109 shares of the specialty pharmaceutical company’s stock worth $561,000 after buying an additional 93,284 shares during the period. Point72 Asset Management L.P. raised its position in KemPharm by 20.4% in the second quarter. Point72 Asset Management L.P. now owns 383,106 shares of the specialty pharmaceutical company’s stock worth $1,525,000 after buying an additional 65,030 shares during the period. Arete Wealth Advisors LLC raised its position in KemPharm by 5.8% in the first quarter. Arete Wealth Advisors LLC now owns 1,044,344 shares of the specialty pharmaceutical company’s stock worth $15,143,000 after buying an additional 57,233 shares during the period. Menta Capital LLC raised its position in KemPharm by 312.3% in the second quarter. Menta Capital LLC now owns 47,041 shares of the specialty pharmaceutical company’s stock worth $187,000 after buying an additional 35,631 shares during the period. Finally, Parkwood LLC purchased a new position in KemPharm during the second quarter worth $107,000. Institutional investors and hedge funds own 42.65% of the company’s stock.
Shares of KemPharm (NASDAQ:KMPH) opened at 4.39 on Wednesday. The company has a 50-day moving average of $4.67 and a 200 day moving average of $7.67. The stock’s market cap is $64.30 million. KemPharm has a one year low of $3.52 and a one year high of $21.30.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. On average, equities analysts forecast that KemPharm will post ($1.78) earnings per share for the current fiscal year.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.